

Development Data for mRNA & Small Molecule Immunotherapies for Treating Cancer: Regen BioPharma,; Stock Symbol: RGBP

Useful Data in Development of mRNA and Small Molecule Immunotherapies for Treating Cancer and Autoimmune Disorders: , Stock Symbol: RGBP \$RGBP

LA MESA, CALIFORNIA, UNITED STATES, October 24, 2023 /EINPresswire.com/ -- Unexpected and Potentially Extremely Useful Data in Development of mRNA and Small Molecule Immunotherapies for Treating Cancer and Autoimmune Disorders: Regen BioPharma, [\(OTC-PINK: RGBP\)](#) and [\(OTC-PINK: RBP\)](#)

Advancing Therapies for Treating Cancer and Autoimmune Disorders by Modulating the Immune Checkpoint NR2F6.


Applying a Genetic Approach to Regulating NR2F6 Levels in Human T Cells.

Additional Work for Blood Disorders, Cellular Immunotherapy, Modulating Key Molecular Processes in Cancer Stem Cell and Repairing Damaged Bone Marrow.

Received Unexpected and Potentially Extremely Useful Data on Experimental Studies on the Company's DuraCAR CAR T-Cell Therapeutic.

Studies Demonstrated That T Cells Which Express the Chimeric Antigen Receptor (CAR) Construct Expressing siRNA for NR2F6 can be Successfully Created.

Second Unrelated qRT-PCR Testing Underway to Determine if NR2F6 mRNA is Elevated or Inhibited by Company's CAR in T-Cells.




Regen BioPharma, ([OTC-PINK: RGBP](#)) and ([OTC-PINK: RGBPP](#)) is a biotechnology company working in the immunology and immunotherapy space. RGBP is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, RGBP is developing mRNA and small molecule therapies for treating cancer and autoimmune disorders.

RGBP plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, RGBP is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. RGBP is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).



We know our shareholders are anxious to hear about our results surrounding modifying NR2F6 levels in CAR T-cells and we will get this data out as soon as we can"

Dr. David Koos, Chairman and CEO of \$RGBP



Regen BioPharma Stock Symbol: RGBP \$RGBP

Product Pipeline

Program	Indication	Milestone			
		Pre-clinical Testing	IND Submitted	IND Approved	Phase I/II
HemaXellerate Personalized Stem Cells	Aplastic Anemia	IND #15376			
dCellVax Gene Silencing of IDO	Breast Cancer	IND #16200			
tCellVax Ex vivo siRNA NR2F6	Solid Tumors	IND #16928			
DiffronC In vivo siRNA NR2F6	MDS, Solid Tumors				
KimerApt Bispecific aptamers	Solid Tumors				
DuraCAR Gene-silenced CAR-T cells	Solid and Liquid Tumors				

Regen BioPharma Product Pipeline RGBP \$RGBP

Intellectual Property – Issued Patents

Patent Number	Patent Title	Date Granted
US-11,324,719-B2	Small molecule agonists and antagonists of NR2F6 activity in humans	2022-10-05
US-11,241,427-B2	Small molecule modulators of NR2F6 Activity	2022-02-08
US-11,141,471-B2	Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells	2021-10-12
US-11,090,332-B2	Antigen specific mRNA cellular cancer vaccines	2021-09-17
US-11,053,503-B2	Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition	2021-07-06
US-10,088,485-B2	Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand	2018-10-02
US-9,091,696-B2	Modulation of NR2F6 and methods and uses thereof	2015-07-28
US-8,389,708-B2	Method of cancer treatment using siRNA silencing	2013-03-05
US-8,263,571-B2	Gene silencing of the brother of the regulator of imprinted sites (BORIS)	2012-09-11


Regen BioPharma Patents RGBP \$RGBP

RGBP Expects Second Phase of Confirmatory Study Shortly

On October 18th RGBP reported on its current development of a genetic approach to regulating NR2F6 levels in human T cells. RGBP has recently received unexpected and potentially extremely useful data from one of its contract research organizations (CRO) retained to perform experimental studies on the Company's DuraCAR CAR T-cell therapeutic. These studies demonstrated that T cells which express the chimeric antigen receptor (CAR)

construct expressing siRNA for NR2F6 can be successfully created.

"A second unrelated CRO is currently performing qRT-PCR tests to determine if NR2F6 mRNA is elevated or inhibited by our CAR in T-Cells," says Dr. Harry Lander, Chief Scientific Consultant to RGBP." If NR2F6 mRNA is suppressed (stimulating certain immune functions) then this product shows potential for treatment of cancer and if NR2F6 mRNA is elevated (suppressing certain immune functions) then the product shows potential for treatment of autoimmune disorders."



Scientific Advisory Board

Ravinder Reddy, Ph.D. Dr. Reddy is currently a Professor of Radiology and the Director of the Center for Advanced Metabolic Imaging in Prec... Know more	Mohammad Haris, Ph.D. Dr. Haris is an Associate Professor in the Center for Advanced Metabolic Imaging in Precision Medicine, Department of... Know more	Stefano Bertuzzi, PhD, MPH Dr. Bertuzzi is currently the Executive Director of the American Society for Cell Biology and has been named Execut... Know more
David A. Suhay, PhD Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus. Know more	Weiping Min, MD, PhD Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejec... Know more	Amit Patel, MD, MSc Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah. Know more
Santosh Kesari, MD, PhD Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center, and the Translational Neuro-Oncology Labo... Know more	Rohit Duggal, PhD 17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer ste... Know more	William S. Blaner, PhD Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids. He... Know more

Regen BioPharma Scientific Advisory Board RGBP \$RGBP

Once RGBP receives the data, it will analyze the results and report the findings in a press release in order to keep the company's shareholders informed of its progress.

RGBP Receives First Phase of Confirmatory Study

CAR-T Cells Created

On October 10th RGBP issued an announcement covering its previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (<https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html>) while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders <https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html>.

RGBP then reported it had received the first set of confirmatory data which demonstrates that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 were successfully created. In addition, the siRNA that is designed into the CAR T-cell was very highly expressed. Subsequent RGBP studies will determine if the expression of NR2F6 mRNA is suppressed or enhanced as a result of the high expression of siRNA.

"This is a major accomplishment in moving this model forward into therapies because in order to test whether we can genetically manipulate NR2F6 levels, we have to be able to produce a CAR T-cell where we demonstrate expression of this siRNA," says Dr. Harry Lander, Chief Scientific Consultant to RGBP. "We are excited to see the results on NR2F6 expression. If it is inhibited, we

will focus on using these DuraCAR cells as originally envisioned - to attack solid tumors. If it is enhanced, we will begin re-tooling these cells to treat autoimmune disorders."

For more information on \$RGBP visit: <http://www.regenbiopharmainc.com>

DISCLAIMER: CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated \$500 by a third party for dissemination of this article.

SOURCE: CorporateAds.com

David R. Koos, Ph.D.
Regen BioPharma Inc.
+1 619-722-5505

[email us here](#)

Visit us on social media:

[Twitter](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/663547112>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.